Business Standard

Cipla surges 5% on USFDA approval for dimethyl fumarate DR capsules

The drug, indicated for treatment of relapsing forms of multiple sclerosis, had annual US sales of US$3.8 billion as per IQVIA MAT July 2020.

v
Premium

Meanwhile, Cipla's shares hit a record high of Rs 819 on September 18, 2020, after Perrigo announced that it would recall its gProAir (Albuterol) MDI inhaler from the US market.

SI Reporter Mumbai
Shares of Cipla surged 5 per cent to Rs 772 on the BSE in the intra-day trade on Friday after the company said it has received US Food & Drug Administration (USFDA) approval for the generic version of Biogens Tecfidera (Dimethyl Fumarate) DR capsules in the US.

The drug, indicated for the treatment of relapsing forms of multiple sclerosis, had annual US sales of US$3.8 billion as per IQVIA MAT July 2020.

“Cipla’s Dimethyl Fumarate DR capsules 120mg, 240mg, and 120mg/240mg Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc.’s Tecfidera,” the company said in a regulatory

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 25 2020 | 12:57 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com